Aura Biosciences to repurchase 6.9M shares at $5.64

Aura Biosciences, Inc. entered into a Repurchase Agreement with Matrix Capital Management Master Fund to buy back up to 6,922,870 shares of its common stock in a privately negotiated transaction.

Rhea-AI Filing Summary

Aura Biosciences, Inc. entered into a Repurchase Agreement with Matrix Capital Management Master Fund to buy back up to 6,922,870 shares of its common stock in a privately negotiated transaction. The repurchase price per share will match the price at which underwriters purchase shares in the company’s separately announced underwritten equity offering, which was set at $5.64 per share.

The company plans to fund the repurchase using a portion of net proceeds from the equity offering that exceed $200 million, after underwriting discounts and commissions. Matrix held approximately 10.8% of Aura’s outstanding common stock as of April 15, 2026. The stock repurchase is subject to the successful closing of the equity offering and other conditions and may not occur. Aura also disclosed preliminary cash, cash equivalents and marketable securities of about $114.7 million as of March 31, 2026, which are unaudited and subject to final accounting.

Insights

Capital structure analyst

Aura pairs a large equity raise with a targeted 6.9M-share buyback from a 10.8% holder.

Aura Biosciences agreed to repurchase up to 6,922,870 shares from Matrix at the $5.64 per-share price used in its underwritten equity offering. Funding will come from equity offering net proceeds above $200 million, after underwriting costs, linking the buyback directly to new capital raised.

Before these transactions, Matrix owned about 10.8% of Aura’s outstanding common stock as of April 15, 2026, so completing the repurchase would remove a sizable shareholder and potentially reduce future selling pressure from that holder. The deal is conditioned on the equity offering closing and other customary conditions, so actual impact depends on successful completion.

Aura also reported preliminary cash, cash equivalents and marketable securities of roughly $114.7 million as of March 31, 2026, giving a snapshot of its liquidity before the equity raise and potential repurchase. Further filings after the quarter ending June 30, 2026 are expected to include the full Repurchase Agreement and more complete financials.

8-K Event Classification

3 items: 1.01, 2.02, 8.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Share repurchase size: 6,922,870 shares Repurchase price per share: $5.64 per share Equity offering proceeds threshold: $200 million +2 more

5 metrics

Share repurchase size 6,922,870 shares Maximum common shares to be repurchased from Matrix

Repurchase price per share $5.64 per share Equals underwriters’ purchase price in equity offering

Equity offering proceeds threshold $200 million Net proceeds above this amount expected to fund repurchase

Matrix ownership stake 10.8% of outstanding shares Based on shares outstanding as of April 15, 2026

Preliminary liquidity $114.7 million Cash, cash equivalents and marketable securities as of March 31, 2026

Key Terms

Repurchase Agreement, underwritten equity offering, Audit Committee, forward-looking statements, +1 more

5 terms

Repurchase Agreement financial

"entered into a stock purchase agreement (the “Repurchase Agreement”) pursuant to which the Company has agreed to repurchase"

A repurchase agreement is a short-term loan in which one party sells a financial security (often government bonds) to another with a promise to buy it back at a slightly higher price on a set future date. Think of it like a pawn-shop loan using safe securities as collateral; it matters to investors because these agreements are a core way banks and funds get quick cash, influence short-term interest rates, and create exposure to counterparty and liquidity risk.

underwritten equity offering financial

"sale of its common stock in the underwritten equity offering that the Company separately announced"

Audit Committee financial

"were reviewed and approved by the audit committee (the “Audit Committee”) of the Company’s Board of Directors"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

forward-looking statements regulatory

"Statements contained under this Item 1.01 regarding matters that are not historical facts are “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock repurchase did Aura Biosciences (AURA) announce with Matrix Capital?

Aura Biosciences agreed to repurchase up to 6,922,870 shares from Matrix Capital in a privately negotiated deal. The price per share equals the underwriters’ purchase price in Aura’s equity offering, disclosed as $5.64 per share, and the transaction is subject to closing conditions.

How will Aura Biosciences (AURA) fund its share repurchase from Matrix?

Aura plans to fund the Matrix repurchase using net proceeds above $200 million from its underwritten equity offering, after underwriting discounts and commissions. Only the portion of net proceeds exceeding that $200 million threshold is expected to be applied to the stock buyback.

How significant is Matrix’s ownership stake in Aura Biosciences (AURA)?

Matrix held approximately 10.8% of Aura Biosciences’ outstanding common stock based on shares outstanding as of April 15, 2026. The planned repurchase of up to 6,922,870 shares is expected to cover the shares Aura believes Matrix holds as of the agreement date.

What preliminary cash position did Aura Biosciences (AURA) report?

Aura estimated cash, cash equivalents and marketable securities of about $114.7 million as of March 31, 2026. This figure is preliminary, unaudited, and may change once the company completes its accounting procedures for the quarter ended March 31, 2026.

When is Aura Biosciences’ (AURA) share repurchase from Matrix expected to close?

The stock repurchase is expected to close no earlier than two business days after the equity offering closes. Completion is conditioned on the successful closing of the underwritten equity offering and other agreed conditions, and may ultimately not occur as described.

Who approved Aura Biosciences’ (AURA) Repurchase Agreement with Matrix Capital?

The Repurchase Agreement was reviewed and approved by Aura’s Audit Committee and Board of Directors. The Audit Committee oversees related party transactions and consists of three independent directors who are not affiliated with Matrix, and then recommended Board approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:20 PM EDT Learn about SEC filing dates

false 0001501796 0001501796 2026-04-30 2026-04-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2026

Aura Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40971		32-0271970
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

80 Guest Street
Boston, Massachusetts				02135
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 500-8864

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		AURA		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On April 30, 2026, Aura Biosciences, Inc. (the “Company”) and Matrix Capital Management Master Fund, LP (“Matrix”) entered into a stock purchase agreement (the “Repurchase Agreement”) pursuant to which the Company has agreed to repurchase, in a privately negotiated transaction, up to 6,922,870 shares of its common stock, which the Company believes represents all shares of its common stock held by Matrix as of the date of this Current Report on Form 8-K (this “Current Report”). Pursuant to the Repurchase Agreement, the Company expects to fund the repurchase using a portion of the net proceeds from the sale of its common stock in the underwritten equity offering that the Company separately announced on May 4, 2026 (the “Equity Offering”), after deducting underwriting discounts and commissions, that are in excess of $200 million, inclusive of any such net proceeds that the Company may receive in connection with the exercise, if any, of the underwriters’ option to purchase additional shares of the Company’s common stock in the Equity Offering. The Company will repurchase the shares from Matrix at a price per share equal to the price per share at which the underwriters will purchase shares from the Company in the Equity Offering (the “Stock Repurchase”), subject to certain conditions. Based on such price per share of the Equity Offering, which the Company separately announced on May 4, 2026 as $5.64, the Company expects to repurchase the 6,922,870 shares of the common stock held by Matrix. The shares being repurchased will become authorized but unissued shares. Prior to giving effect to the Equity Offering and the Stock Repurchase, Matrix held approximately 10.8% of our outstanding common stock based on the number of shares of common stock outstanding as of April 15, 2026.

The closing of the Stock Repurchase is expected to occur no earlier than two business days after the closing of the Equity Offering.

The Stock Repurchase is conditioned upon the closing of the Equity Offering and certain other conditions. We cannot provide any assurance that the Stock Repurchase will occur on the terms described herein, or at all. The description of, and other information in this Current Report regarding, the Stock Repurchase are included for informational purposes only. Nothing in this Current Report should be construed as an offer (i) to sell, or the solicitation of an offer to purchase, any of our common stock that we may repurchase, or (ii) to repurchase, or the solicitation of an offer to sell, any of our common stock.

The Repurchase Agreement and related arrangements and transactions were reviewed and approved by the audit committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”), which is charged with reviewing related party transactions, and is composed of three independent directors who are not affiliated with Matrix. Upon the recommendation by the Audit Committee, the Board also approved such transaction.

The foregoing descriptions of the Repurchase Agreement does not purport to be complete and is qualified in its entirety by the full text of the Repurchase Agreement, a copy of which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.

Cautionary Note Regarding Forward Looking Statements

Statements contained under this Item 1.01 regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the completion of the Equity Offering, Matrix share ownership, the satisfaction of customary closing conditions related to the Equity Offering and Stock Repurchase and the planned use of the net proceeds from the Equity Offering to effect the Stock Repurchase.

Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, risks and uncertainties associated with the consummation of the Equity Offering and Stock Repurchase, the completion of the Equity Offering and Stock Repurchase on the anticipated terms or at all, the planned use of the net proceeds from the Equity Offering to effect the Stock Repurchase, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the Equity Offering and Stock Repurchase, and general economic conditions. These risks, uncertainties, and other factors include those risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) and in subsequent filings made by the Company with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained under this Item 1.01 in the event of new information, future developments or otherwise. These forward-looking statements are based on the Company’s current expectations and speak only as of the date hereof and no representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.

Item 2.02. Results of Operations and Financial Condition.

The information contained in Item 8.01 of this Current Report, to the extent required, is incorporated into this Item 2.02 by reference and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

The Company is providing the following information about its preliminary cash, cash equivalents and marketable securities as of March 31, 2026.

Based upon preliminary estimates and currently available information, the Company estimates that its cash, cash equivalents and marketable securities were approximately $114.7 million as of March 31, 2026. This amount has not been audited, reviewed, or compiled by the Company’s independent registered public accounting firm. The Company’s actual cash, cash equivalents and marketable securities as of March 31, 2026 may differ from these amounts after the Company completes its accounting procedures for the quarter ended March 31, 2026.

The information in Item 8.01 of this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in the filing, unless specifically stated so therein.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Aura Biosciences, Inc.
Date: May 4, 2026				By:		/s/ Anthony Gibney
						Anthony Gibney
						Chief Financial and Business Officer
						(Principal Financial Officer)

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB